14.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$14.15
Aprire:
$14.15
Volume 24 ore:
507.35K
Relative Volume:
0.53
Capitalizzazione di mercato:
$595.49M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-2.8577
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
+0.62%
1M Prestazione:
+0.07%
6M Prestazione:
-74.16%
1 anno Prestazione:
-68.72%
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KROS
Keros Therapeutics Inc
|
14.66 | 582.83M | 0 | -168.05M | -146.15M | -5.13 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
2024-12-16 | Reiterato | Oppenheimer | Outperform |
2024-12-13 | Reiterato | H.C. Wainwright | Buy |
2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
2024-11-05 | Iniziato | Jefferies | Buy |
2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
2024-09-23 | Iniziato | Guggenheim | Buy |
2024-06-25 | Iniziato | Oppenheimer | Outperform |
2024-02-21 | Iniziato | William Blair | Outperform |
2023-12-08 | Iniziato | Wells Fargo | Overweight |
2023-07-31 | Iniziato | Wedbush | Outperform |
2023-07-26 | Iniziato | BofA Securities | Buy |
2023-02-14 | Iniziato | Cowen | Outperform |
2022-10-18 | Iniziato | Truist | Buy |
2022-07-26 | Iniziato | BTIG Research | Buy |
2020-12-08 | Reiterato | H.C. Wainwright | Buy |
2020-05-04 | Iniziato | H.C. Wainwright | Buy |
2020-05-04 | Iniziato | Jefferies | Buy |
2020-05-04 | Iniziato | Piper Sandler | Overweight |
2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat
ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World
D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Wedbush Reiterates Neutral Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - Defense World
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus
TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa
Janus Henderson Group PLC Has $226,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being - simplywall.st
Keros Therapeutics Shares Drop; Cibotercept Development Halted, Jobs Cut - marketscreener.com
KROS Halts Development of Cibotercept in PAH After Safety Concer - GuruFocus
Keros Therapeutics Announces Corporate Restructuring - citybiz
Keros Therapeutics (KROS) Restructures Focus, Faces Modest Cost Savings | KROS Stock News - GuruFocus
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% - Benzinga
Keros stock as mid-stage trial for PAH therapy ends (KROS) - Seeking Alpha
Keros Therapeutics, Inc. Announces Corporate Restructuring - marketscreener.com
Keros Therapeutics Announces Tropos Topline Data And Corporate Restructuring - marketscreener.com
Keros Therapeutics, Inc. Announces TROPOS Topline Data - marketscreener.com
Keros Therapeutics halts PAH drug development, cuts workforce - Investing.com Australia
KROS Announces Workforce Reduction and Strategic Evaluation | KROS Stock News - GuruFocus
Keros Therapeutics halts cibotercept development, plans workforce reduction By Investing.com - Investing.com Canada
Keros Therapeutics Discontinues Cibotercept Development in PAH and Announces Corporate Restructuring - Nasdaq
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring - Yahoo Finance
1 Stock That Turned $1,000 Into $32 Million - The Globe and Mail
Woodline Partners LP Has $6.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
D. E. Shaw & Co. Inc. Sells 174,189 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Millennium Management LLC Raises Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros secures Glass Lewis support for director nominees By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Invests $730,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Northern Trust Corp Buys 30,111 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros secures Glass Lewis support for director nominees - Investing.com Australia
Keros Therapeutics Urges Stockholders to Vote "FOR" Director Nominees Amid Proxy Contest with ADAR1 - Nasdaq
Leading Independent Proxy Advisory Firm Glass Lewis - GlobeNewswire
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of ... - Bluefield Daily Telegraph
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees - GlobeNewswire Inc.
Keros Therapeutics (KROS) Target Price Adjusted by BofA Analyst | KROS Stock News - GuruFocus
Twinbeech Capital LP Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
(KROS) Trading Signals - news.stocktradersdaily.com
3 Brilliant Stocks to Buy With $200 and Hold for 5 Years - The Globe and Mail
Janus Henderson Group PLC Sells 77,803 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
TFG Asset Management GP Ltd Acquires Shares of 103,000 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Tema Etfs LLC Makes New $565,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $37.00 Average Target Price from Analysts - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Northern Trust Corp Increases Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):